Claire Elizabeth Hooper
Directeur des opérations chez 37 Clinical Ltd.
Profil
Claire Elizabeth Hooper is currently the Chief Operating Officer at 37 Clinical Ltd.
She previously worked as a Director at Sensiia Ltd.
and as a Non-Executive Director at Abcodia Ltd.
Postes actifs de Claire Elizabeth Hooper
| Sociétés | Poste | Début |
|---|---|---|
37 Clinical Ltd.
 37 Clinical Ltd. Information Technology ServicesTechnology Services 37 Clinical Ltd. is an AI platform that predicts the onset of infections, adverse events, and physiological decline in advance of the manifest of obvious symptoms. The company is based in Cambridge, UK, and was founded in 2019. The analytics engine has achieved proof-of-concept using temperature data from more than 3,000 people and plans clinical studies in chronic obstructive pulmonary disease (COPD), bronchiectasis, and asthma. The CEO is Gregory Berman. | Directeur des opérations | - |
Anciens postes connus de Claire Elizabeth Hooper
| Sociétés | Poste | Fin |
|---|---|---|
Abcodia Ltd.
 Abcodia Ltd. BiotechnologyHealth Technology Abcodia Ltd. engages in the validation and discovery of molecular biomarkers. The firm works alongside University College London and in partnership with diagnostic, pharmaceutical and technology companies to exploit a prospective serum bank for the purpose of ethical biomarker validation and discovery. The company was founded in 2010 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | 08/06/2018 |
Sensiia Ltd.
 Sensiia Ltd. Electronic Equipment/InstrumentsElectronic Technology Sensiia Ltd. develops consumer telemedicine solutions. Its flagship product, DuoFertility is a stick-on sensor and handheld reader device that tracks specific biometrics like temperature to help women conceive. The firms services combine wearable monitoring that continuously tracks multiple elements of physiological measurement, scientific and medically based data analytics and specialist advisers to provide personalized, positive health outcomes in areas that affect including fertility, sleep disturbance and pain. The company was founded by Shamus Louis Godfrey Husheer, David Naumann, Oriane Elisabeth Chausiaux, Lydia Ferguson, Chafic Ayoub and Scott Robert Mackie in 2006 and is headquartered in Cambridge, the United Kingdom. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Abcodia Ltd.
Abcodia Ltd. BiotechnologyHealth Technology Abcodia Ltd. engages in the validation and discovery of molecular biomarkers. The firm works alongside University College London and in partnership with diagnostic, pharmaceutical and technology companies to exploit a prospective serum bank for the purpose of ethical biomarker validation and discovery. The company was founded in 2010 and is headquartered in London, the United Kingdom. | Health Technology |
Sensiia Ltd.
Sensiia Ltd. Electronic Equipment/InstrumentsElectronic Technology Sensiia Ltd. develops consumer telemedicine solutions. Its flagship product, DuoFertility is a stick-on sensor and handheld reader device that tracks specific biometrics like temperature to help women conceive. The firms services combine wearable monitoring that continuously tracks multiple elements of physiological measurement, scientific and medically based data analytics and specialist advisers to provide personalized, positive health outcomes in areas that affect including fertility, sleep disturbance and pain. The company was founded by Shamus Louis Godfrey Husheer, David Naumann, Oriane Elisabeth Chausiaux, Lydia Ferguson, Chafic Ayoub and Scott Robert Mackie in 2006 and is headquartered in Cambridge, the United Kingdom. | Electronic Technology |
37 Clinical Ltd.
37 Clinical Ltd. Information Technology ServicesTechnology Services 37 Clinical Ltd. is an AI platform that predicts the onset of infections, adverse events, and physiological decline in advance of the manifest of obvious symptoms. The company is based in Cambridge, UK, and was founded in 2019. The analytics engine has achieved proof-of-concept using temperature data from more than 3,000 people and plans clinical studies in chronic obstructive pulmonary disease (COPD), bronchiectasis, and asthma. The CEO is Gregory Berman. | Technology Services |
